Does the media prefer JANX or AKBA?

In the previous week, Janux Therapeutics had 1 more articles in the media than Akebia Therapeutics. MarketBeat recorded 3 mentions for Janux Therapeutics and 2 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.27 beat Janux Therapeutics' score of 0.16 indicating that Akebia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Akebia Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, ANL or AKBA?

Akebia Therapeutics has higher revenue and earnings than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 199.51 -$35.53M N/A N/A Akebia Therapeutics $219.06M 1.14 -$5.34M -$0.11 N/A

Does the media favor ANL or AKBA?

In the previous week, Adlai Nortye had 6 more articles in the media than Akebia Therapeutics. MarketBeat recorded 8 mentions for Adlai Nortye and 2 mentions for Akebia Therapeutics. Adlai Nortye's average media sentiment score of 0.57 beat Akebia Therapeutics' score of 0.27 indicating that Adlai Nortye is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akebia Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ALMS or AKBA more profitable?

Akebia Therapeutics has a net margin of -13.54% compared to Alumis' net margin of -5,933.46%. Akebia Therapeutics' return on equity of -88.88% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -5,933.46% -93.15% -74.50% Akebia Therapeutics -13.54% -88.88% -7.74%

Does the media favor ALMS or AKBA?

In the previous week, Alumis and Alumis both had 2 articles in the media. Alumis' average media sentiment score of 0.80 beat Akebia Therapeutics' score of 0.27 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akebia Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SLDB or AKBA?

In the previous week, Solid Biosciences had 2 more articles in the media than Akebia Therapeutics. MarketBeat recorded 4 mentions for Solid Biosciences and 2 mentions for Akebia Therapeutics. Solid Biosciences' average media sentiment score of 0.76 beat Akebia Therapeutics' score of 0.27 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akebia Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Akebia Therapeutics (AKBA) Competitors

$0.90 -0.02 (-1.74%)

As of 02:49 PM Eastern

Compare

AKBA vs. JANX, ANL, ALMS, ABUS, and SLDB

Should you buy Akebia Therapeutics stock or one of its competitors? Akebia Therapeutics's main competitors and comparable companies include Janux Therapeutics (JANX), Adlai Nortye (ANL), Alumis (ALMS), Arbutus Biopharma (ABUS), and Solid Biosciences (SLDB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Akebia Therapeutics compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Akebia Therapeutics has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	99.54	-$113.62M	-$1.64	N/A
Akebia Therapeutics	$219.06M	1.14	-$5.34M	-$0.11	N/A

Janux Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Janux Therapeutics' return on equity of -11.89% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

In the previous week, Janux Therapeutics had 1 more articles in the media than Akebia Therapeutics. MarketBeat recorded 3 mentions for Janux Therapeutics and 2 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.27 beat Janux Therapeutics' score of 0.16 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akebia Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Janux Therapeutics presently has a consensus price target of $36.46, suggesting a potential upside of 123.97%. Akebia Therapeutics has a consensus price target of $3.90, suggesting a potential upside of 331.89%. Given Akebia Therapeutics' higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Janux Therapeutics has a beta of 2.53, suggesting that its stock price is 153% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

Summary

Janux Therapeutics beats Akebia Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Akebia Therapeutics compare to Adlai Nortye?

Adlai Nortye (NASDAQ:ANL) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Adlai Nortye currently has a consensus price target of $29.50, suggesting a potential upside of 90.45%. Akebia Therapeutics has a consensus price target of $3.90, suggesting a potential upside of 331.89%. Given Akebia Therapeutics' higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Adlai Nortye has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

Akebia Therapeutics has higher revenue and earnings than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	199.51	-$35.53M	N/A	N/A
Akebia Therapeutics	$219.06M	1.14	-$5.34M	-$0.11	N/A

In the previous week, Adlai Nortye had 6 more articles in the media than Akebia Therapeutics. MarketBeat recorded 8 mentions for Adlai Nortye and 2 mentions for Akebia Therapeutics. Adlai Nortye's average media sentiment score of 0.57 beat Akebia Therapeutics' score of 0.27 indicating that Adlai Nortye is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akebia Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adlai Nortye has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Adlai Nortye's return on equity of 0.00% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 4.3% of Akebia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Adlai Nortye beats Akebia Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Akebia Therapeutics compare to Alumis?

Alumis (NASDAQ:ALMS) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

33.9% of Akebia Therapeutics shares are held by institutional investors. 33.7% of Alumis shares are held by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Akebia Therapeutics has a net margin of -13.54% compared to Alumis' net margin of -5,933.46%. Akebia Therapeutics' return on equity of -88.88% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-5,933.46%	-93.15%	-74.50%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

Akebia Therapeutics has higher revenue and earnings than Alumis. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	38.27	-$243.32M	-$3.86	N/A
Akebia Therapeutics	$219.06M	1.14	-$5.34M	-$0.11	N/A

Alumis has a beta of -0.81, indicating that its stock price is 181% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

In the previous week, Alumis and Alumis both had 2 articles in the media. Alumis' average media sentiment score of 0.80 beat Akebia Therapeutics' score of 0.27 indicating that Alumis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akebia Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alumis presently has a consensus target price of $33.27, suggesting a potential upside of 367.84%. Akebia Therapeutics has a consensus target price of $3.90, suggesting a potential upside of 331.89%. Given Alumis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Alumis is more favorable than Akebia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Alumis and Akebia Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Akebia Therapeutics compare to Arbutus Biopharma?

Akebia Therapeutics (NASDAQ:AKBA) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Arbutus Biopharma has a net margin of 84.22% compared to Akebia Therapeutics' net margin of -13.54%. Arbutus Biopharma's return on equity of 90.98% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-13.54%	-88.88%	-7.74%
Arbutus Biopharma	84.22%	90.98%	82.34%

Akebia Therapeutics has higher revenue and earnings than Arbutus Biopharma. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$219.06M	1.14	-$5.34M	-$0.11	N/A
Arbutus Biopharma	$14.08M	68.59	-$33.50M	$0.79	6.17

Akebia Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

Akebia Therapeutics presently has a consensus target price of $3.90, indicating a potential upside of 331.89%. Arbutus Biopharma has a consensus target price of $5.00, indicating a potential upside of 2.56%. Given Akebia Therapeutics' higher possible upside, equities research analysts clearly believe Akebia Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Akebia Therapeutics had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 2 mentions for Akebia Therapeutics and 1 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.76 beat Akebia Therapeutics' score of 0.27 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Akebia Therapeutics	Neutral
Arbutus Biopharma	Very Positive

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Arbutus Biopharma beats Akebia Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Akebia Therapeutics compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

In the previous week, Solid Biosciences had 2 more articles in the media than Akebia Therapeutics. MarketBeat recorded 4 mentions for Solid Biosciences and 2 mentions for Akebia Therapeutics. Solid Biosciences' average media sentiment score of 0.76 beat Akebia Therapeutics' score of 0.27 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akebia Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Akebia Therapeutics has higher revenue and earnings than Solid Biosciences. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
Akebia Therapeutics	$219.06M	1.14	-$5.34M	-$0.11	N/A

Solid Biosciences currently has a consensus price target of $18.69, indicating a potential upside of 159.44%. Akebia Therapeutics has a consensus price target of $3.90, indicating a potential upside of 331.89%. Given Akebia Therapeutics' higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Solid Biosciences has a beta of 2.44, suggesting that its stock price is 144% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

Solid Biosciences has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Solid Biosciences' return on equity of -71.35% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Solid Biosciences beats Akebia Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Akebia Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKBA vs. The Competition

Export

Metric	Akebia Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$250.23M	$3.91B	$7.25B	$13.16B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-8.21	14.06	274.69	25.81
Price / Sales	1.14	1,318.94	681.05	110.54
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	7.53	15.30	10.45	6.32
Net Income	-$5.34M	-$22.86M	$3.48B	$359.77M
7 Day Performance	-1.39%	-3.03%	-1.33%	-0.15%
1 Month Performance	-5.78%	-9.12%	-4.58%	-4.08%
1 Year Performance	-66.68%	31.34%	16.32%	6.16%

Akebia Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKBA Akebia Therapeutics	3.209 of 5 stars	$0.90 -1.7%	$3.90 +331.9%	-66.8%	$250.23M	$219.06M	N/A	194
JANX Janux Therapeutics	2.4035 of 5 stars	$17.01 +2.5%	$36.46 +114.4%	-27.0%	$1.01B	$10M	N/A	113
ANL Adlai Nortye	1.9642 of 5 stars	$15.57 -1.1%	$29.50 +89.5%	+831.2%	$1.01B	$5M	N/A	109	News Coverage Gap Up
ALMS Alumis	3.8873 of 5 stars	$7.90 +1.7%	$33.27 +321.2%	+76.1%	$1.01B	$24.05M	N/A	239
ABUS Arbutus Biopharma	1.5828 of 5 stars	$5.00 -0.2%	$5.00	+8.7%	$992.51M	$14.08M	6.33	19	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKBA) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akebia Therapeutics (AKBA) Competitors

AKBA vs. JANX, ANL, ALMS, ABUS, and SLDB

How does Akebia Therapeutics compare to Janux Therapeutics?

Summary

How does Akebia Therapeutics compare to Adlai Nortye?

Summary

How does Akebia Therapeutics compare to Alumis?

Summary

How does Akebia Therapeutics compare to Arbutus Biopharma?

Summary

How does Akebia Therapeutics compare to Solid Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA vs. The Competition

Akebia Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Akebia Therapeutics (AKBA) Competitors

AKBA vs. JANX, ANL, ALMS, ABUS, and SLDB

How does Akebia Therapeutics compare to Janux Therapeutics?

Which has higher valuation and earnings, JANX or AKBA?

Is JANX or AKBA more profitable?

Does the media prefer JANX or AKBA?

Do analysts prefer JANX or AKBA?

Do institutionals & insiders have more ownership in JANX or AKBA?

Which has more risk & volatility, JANX or AKBA?

Summary

How does Akebia Therapeutics compare to Adlai Nortye?

Do analysts rate ANL or AKBA?

Which has more volatility and risk, ANL or AKBA?

Which has preferable earnings & valuation, ANL or AKBA?

Does the media favor ANL or AKBA?

Is ANL or AKBA more profitable?

Do institutionals & insiders hold more shares of ANL or AKBA?

Summary

How does Akebia Therapeutics compare to Alumis?

Do insiders & institutionals have more ownership in ALMS or AKBA?

Is ALMS or AKBA more profitable?

Which has higher valuation & earnings, ALMS or AKBA?

Which has more volatility & risk, ALMS or AKBA?

Does the media favor ALMS or AKBA?

Do analysts prefer ALMS or AKBA?

Summary

How does Akebia Therapeutics compare to Arbutus Biopharma?

Is AKBA or ABUS more profitable?

Which has preferable earnings & valuation, AKBA or ABUS?

Which has more risk and volatility, AKBA or ABUS?

Do analysts rate AKBA or ABUS?

Does the media prefer AKBA or ABUS?

Do institutionals and insiders have more ownership in AKBA or ABUS?

Summary

How does Akebia Therapeutics compare to Solid Biosciences?

Does the media prefer SLDB or AKBA?

Which has better earnings & valuation, SLDB or AKBA?

Do analysts prefer SLDB or AKBA?

Which has more volatility and risk, SLDB or AKBA?

Is SLDB or AKBA more profitable?

Do institutionals and insiders believe in SLDB or AKBA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA vs. The Competition

Akebia Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools